Guidelines for the hormone treatment of women in the menopausal transition and beyond.

[1]  R. Prentice,et al.  Estrogen plus progestin and risk of venous thrombosis. , 2004, JAMA.

[2]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[3]  H. Taylor,et al.  The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. , 2004, Fertility and sterility.

[4]  R. Lobo.  Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. , 2004, Archives of internal medicine.

[5]  G. B. Lopes,et al.  Effects of estrogen plus progestin on health-related quality of life. , 2004, The New England journal of medicine.

[6]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[7]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[8]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[9]  W. Mack,et al.  Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. , 2003, Atherosclerosis.

[10]  A. Genazzani,et al.  The missing R , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[11]  A. Maclennan,et al.  HT or HRT, that is the question? , 2003, Climacteric : the journal of the International Menopause Society.

[12]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[13]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[14]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[15]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[16]  Graham A. Colditz,et al.  Trends in the Incidence of Coronary Heart Disease and Changes in Diet and Lifestyle in Women , 2000 .

[17]  O. Joakimsen,et al.  Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromsø Study. , 2000, Journal of clinical epidemiology.

[18]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[19]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[20]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[21]  S. Manuck,et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.